4.4 Article

Cognitive and symptomatic predictors of functional disability in schizophrenia

Journal

SCHIZOPHRENIA RESEARCH
Volume 126, Issue 1-3, Pages 257-264

Publisher

ELSEVIER SCIENCE BV
DOI: 10.1016/j.schres.2010.08.007

Keywords

-

Categories

Funding

  1. NIMH [R01MH079800, P50MH080173]
  2. Eli Lilly
  3. Merck
  4. Clinical Data Inc.
  5. GoldenHelix, Inc.
  6. Guide-point Global
  7. Cowen Co.
  8. Astra Zeneca
  9. Otsuka
  10. Pfizer
  11. Dainippon Sumitomo
  12. Azur
  13. Janssen
  14. Lilly

Ask authors/readers for more resources

Background: Neurocognition and negative symptoms play a major role in predicting functional outcomes in patients with schizophrenia. Few studies have assessed the relationship between functional outcomes and the MATRICS consensus cognition battery (MCCB), which will be central to future clinical trials of cognitive enhancing agents. Aims: To assess the role of individual MCCB domains on functional outcomes. Method: 185 stable outpatients with schizophrenia were enrolled and assessed with the MCCB, Social Adjustment Scale-II (SAS-11) and Multidimensional Scale for Independent Functioning (MSIF), along with BPRS and SANS. Results: We found significant relationships between MCCB neurocognitive domain scores, negative symptoms and aspects of functional outcome in schizophrenia. Specifically, we found that work/education functioning is predicted by working memory performance and negative symptoms; residential status (independent living) is predicted by verbal memory scores; and social functioning is predicted by social cognition, attention and negative symptoms. We also found that negative symptom severity was not related to residential status, even though it demonstrated the predicted associations to work and social functioning. Conclusion: To our knowledge, this is the first study to assess cognition and functional outcomes using MCCB, SAS II and MSIF. Our results extend prior work and help provide more data on the relationships between cognition, symptoms and functional outcome using real world measures. (C) 2010 Published by Elsevier B.V.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available